Ramsay Health Care Ltd
ASX:RHC

Watchlist Manager
Ramsay Health Care Ltd Logo
Ramsay Health Care Ltd
ASX:RHC
Watchlist
Price: 36.36 AUD 0.44% Market Closed
Market Cap: AU$8.4B

Ramsay Health Care Ltd
Investor Relations

Ramsay Health Care Ltd, a behemoth in the healthcare sector, sprouted from humble beginnings in a small Australian town, eventually unfolding its reach across the globe. Founded by Paul Ramsay in 1964, the company has grown to become one of the largest private hospital operators worldwide. It runs a vast network of hospitals, day surgery centers, and primary care facilities, welcoming millions of patients through its doors annually. Operating in markets like Australia, Europe, and parts of Asia, Ramsay thrives on the essential and ever-growing demand for quality healthcare services. The company focuses not only on delivering acute care but also engages in multidisciplinary medical and surgical treatments, serving as a critical backbone supporting public health systems straining under demand pressures.

Ramsay Health Care generates its revenue primarily through patient services, the bulk of which comes from hospital admissions, procedures, and ancillary services such as physiotherapy and pharmacy operations. The company has strategically positioned itself in the private healthcare sector, catering to those willing or necessitated to utilize its vast array of medical services when public system waiting times are unavoidably long. Furthermore, it derives additional income through partnerships and joint ventures, bolstering its capability to offer specialized treatments and research initiatives. By continually expanding and optimizing its healthcare facilities, investing in state-of-the-art technology, and maintaining high standards of patient care, Ramsay aims to capitalize on global demographic trends such as aging populations and increasing chronic disease prevalence. Through these strategic endeavors, Ramsay Health Care ensures it remains a vital player in the global health arena, attuned to both clinical advancements and regional health policy changes.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2023
Call Date
May 3, 2023
AI Summary
Q3 2023

Margins Pressured: Despite revenue growth, margins remain below pre-COVID levels due to inflation and slower productivity recovery.

Cost Inflation: Salary and agency staff costs continue to weigh on results, with improvement in workforce shortages but key specialty gaps persist.

Payer Negotiations: Discussions with payers are ongoing and may result in one-off payments, but outcomes and timing remain uncertain, especially in France and the UK.

Productivity Focus: Management emphasized a major focus on regaining pre-pandemic productivity, which is still about 5% below FY19 levels.

UK & France Headwinds: France margins pressured as new tariffs do not fully offset lost subsidies; UK (Elysium) faces agency cost and tariff uncertainty.

Volume Trends: Surgical admissions have rebounded after a weak January, but maternity volumes remain low and mental health recovery will take at least 12 months.

Outlook: Operating environment expected to improve through 2023, with May–June volumes seen as key for margin recovery, but guidance remains cautious.

Reporting Changes: Company will end quarterly updates and return to half-yearly reporting as the environment normalizes.

Key Financials
Digital and Data Investment (Asia Pacific)
$27 million
EBITDA Margin (Australia, Q3)
12.2%
Tariff Increase (France)
5.4%
Tariff Increase (Wales, UK Mental Health)
circa 9%
Productivity (Productive hours per inpatient day)
within 5% of FY19 levels
EBIT (Australia, January)
Positive but very low
Other Earnings Calls

Management

Mr. Andrew Smith B.Com., C.A., J.P., M.B.A.
Chief Financial Officer
No Bio Available
Ms. Kelly Hibbins
Group Head of Investor Relations
No Bio Available
Ms. Henrietta Rowe BECON, L.L.B., M.A.I.C.D.
Group General Counsel & Company Secretary
No Bio Available
Ms. Colleen Harris
Group Chief People Officer
No Bio Available
Mr. Andrew Wearne
Group Chief Risk Officer
No Bio Available
Dr. Rachna Gandhi
Group Chief Transformation & Digital Officer
No Bio Available
Ms. Carmel Monaghan
Chief Executive Officer of Ramsay Australia
No Bio Available
Mr. Pascal Roche
CEO of Ramsay Générale De Santé
No Bio Available
Mr. Nick Costa
Chief Executive Officer of Ramsay UK
No Bio Available
Ms. Joy Chamberlain
Chief Executive Officer of Elysium Healthcare
No Bio Available

Contacts

Address
VICTORIA
ST LEONARDS
Level 7, Tower B,, 7 Westbourne Street
Contacts
+61294333444.0
www.ramsayhealth.com